AndroGel Retrial Awards $3.2 Million to the Plaintiff

AndroGel Retrial Awards $3.2 Million to the Plaintiff

Introduction

In a retrial that started early March, AbbVie was ordered by a federal jury to pay $3.2 million to the plaintiff who claims he suffered a heart attack while using AndroGel. The jury awarded $200,000 compensatory damages and $3 million in punitive damages to the plaintiff.  

The plaintiff had been awarded $150 million in punitive damages in July 2017. However, post-trial motions resulted in the dismissal of the verdict by U.S. District Judge Matthew Kennelly of the Northern District of Illinois, on finding that the jury’s decision was “logically incompatible” with the evidence presented at trial; he further ordered a retrial.

Testosterone Replacement Therapy lawsuits are centralized before U.S. District Judge Matthew Kennelly in the Northern District of Illinois for coordinated discovery and management, as part of a federal multidistrict litigation (MDL) 2545 (In re: Testosterone Replacement Therapy Products Liability Litigation). This litigation involves several drug makers; however, Eli Lilly, Auxilium Pharmaceuticals, Endo Pharmaceuticals, and GlaxoSmithKline have announced settlements to resolve all of the testosterone claims against their companies. The terms of those deals have not yet been reported.